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Recent studies have elucidated the role of lysine-speciﬁc demethylase 1 (LSD1), a member of the histone
demethylases, in epigenetic regulation of tumor suppressing/promoting genes and neoplastic growth.
However, the expression of LSD1 in patients with esophageal squamous cell carcinoma (ESCC) is still
unknown. Here, we reported that LSD1 expression was elevated in cancerous tissue and correlated with
lymph node metastasis and poorer overall survival in patients with ESCC. Compared to EC109 cells, LSD1
expression was unregulated in aggressive cancer cell lines KYSE450 and KYSE150. Knockdown of LSD1
using lentivirus delivery of LSD1-speciﬁc shRNA abrogated the migration and invasion of ESCC cells
in vitro. Further, a LSD1 inhibitor, tranylcypromine, suppressed H3K4me2 demethylation and attenuated
cellular motility and invasiveness in a dose-dependent manner. Taken together, these data suggested that
LSD1 was a potential prognostic maker and may be a molecular target for inhibiting invasion and metas-
tasis in ESCC.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Esophageal cancer is the eighth most common cancer world-
wide [1,2], with advanced esophageal cancer being predictive of
signiﬁcantly poorer prognosis [3]. The 5-year survival rate for
esophageal squamous cell carcinoma (ESCC) is only 5–12.3% in
Europe [4,5]. Therefore, novel prognostic and molecular targets
for therapeutic intervention are rapidly needed for patients with
ESCC.
A wide range of genetic and epigenetic modiﬁcations have been
shown to play a pivotal role in the development and tumorigenesis
of esophageal cancers. These epigenetic changes are associated
with DNA methylation and histone modiﬁcations [6–9]. Under-
standing epigenetic changes may help to identify a novel cancer-
related network that may represent attractive targets for ESCC
treatment and provide new insights into the biological characteris-tics of ESCC. Chromatin with histone tailing is deﬁned as a critical
regulator of gene transcription [6,8]. Histone demethylase lysine
speciﬁc demethylase 1 (LSD1) was the ﬁrst histone demethylase
that was discovered, and is a nuclear homolog of amine oxidases.
LSD1 removes methyl groups frommono- and dimethylated Lysine
(Lys) 4 of histone H3 (H3K4me1/2), and Lys9 of histone H3
(H3K9me1/2) [10]. A recent study uncovered the role of LSD1 in
cell phase transition, suggesting that its over-expression may pro-
mote tumorigenesis [11]. The expression of LSD1 has been associ-
ated with tumor recurrence during therapy in various human
cancers, implicating LSD1 as a tumor promoter. It is of note that
LSD1 is involved in embryonic differentiation [12], proliferation
of pluripotent stem cells [13], HIV infection [14], as well as in
the development and metastasis of cancers [15,16]. Furthermore,
LSD1 is highly expressed in prostate cancer [17,18], bladder cancer
[15], breast cancer [16,19], hepatoma [3], non-small-cell lung can-
cer [20] and hematopoietic tumors [21]. All of these studies imply
that LSD1 may be associated with the pathogenesis of ESCC, how-
ever the expression and signiﬁcance of LSD1 in ESCC is obscure.
In our study, we investigated the expression of LSD1 in ESCC tis-
sues. Then, we tested the role of LSD1 in inducing tumor cell inva-
sion in ESCC cells via genetic elimination or pharmacological
inhibition. Our results provided a novel insight that LSD1 may
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the pathogenesis of ESCC.2. Materials and methods
2.1. Patients and tissue microarray
This study enrolled a total of 134 histopathologically-conﬁrmed
ESCC patients who underwent a resection of esophageal carcinoma
in the Institute of Surgery Research, Daping Hospital afﬁliated to
the Third Military Medical University between 2002 and 2007.
All patients received no previous chemotherapy or radiotherapy
before surgery. A multi-disciplinary team, including an oncosur-
geon, an oncologist, and a radiologist, determined the therapeutic
regimen. The clinicopathological information and patients’ medical
history were documented during postoperative follow-up. The his-
tologically-conﬁrmed ESCC tissues were investigated by micro-ar-
ray. With the exception of cancerous tissues, we also obtained 23
cases of esophageal precancerous lesions, and 29 cases of esopha-
geal normal mucosal tissue. We obtained written consent from all
participants. Our study was approved by ethical review board of
the Third Military Medical University.2.2. Immunohistochemistry (IHC)
Parafﬁn tissue sections (4 lm) were incubated overnight with
an antibody against LSD1 (1:400; Abcam, USA). The slides were
incubated for 30 min with goat anti-rabbit immunoglobulin
(E0432, Abcam) after being washed with Tris-buffered NaCl solu-
tion for 30 min. The percentage of positive cells was determined
by counting 500 cells within ﬁve high-resolution ﬁelds. Immuno-
histochemical staining was evaluated using the semi-quantitative
Remmele scoring system [22], which links the IHC staining inten-
sity (SI) with the percentage of positive cells (PP). SI was scored
according to the following criteria: (0) no positive nuclei, (1) all
the positive nuclei display weak staining, (2) the most stained nu-
clei display moderately positive, (3) the nuclei display intensive
staining. PP was scored between 0 and 4 (0: no positive cells, 1:
less than 10% nuclei display intense staining, 2: 11–50% nuclei, 3:
51–80%, 4: more than 80%). The IHC score was ﬁnally calculated
by SI  PP. According to the IHC score, all patients were classiﬁed
into two groups: low expression level (0–4) and high expression le-
vel (4–12).2.3. Cell culture and protein extraction
Esophageal cancer cell lines, KYSE150, KYSE450 and EC109,
were cultured in RPMI 1640 medium supplemented with 10% fetal
calf serum (FCS). At the indicated time points, total cell protein was
extracted using cell lysis buffer (Beyotime Biotechnology, China).2.4. Knock-down of LSD1 via shRNA-delivered by lentivirus
KYSE450 cells were cultured at a concentration of 3  105 cells/
well for 24 h in RPMI 1640 medium supplemented with 10% FCS.
According to the protocol, lentivirus with green ﬂuorescent protein
(GFP; Sunbio, China) was added to the 6-well plates. In addition,
the lentiviral transfection enhancer (Sunbio, China) was applied
at a concentration of 5 lg/ml. The medium was refreshed after
12-h. Notably, puromycin, a cytotoxic agent, eliminated the unsta-
bly infected cells. The shRNA sequences we used in this study are
listed below: Control: TTC TCC GAA CGT GTC ACG T; LSD1-shRNA1:
GCA GCT CGA CAG TTA CAA A; LSD1-shRNA2: CCA CCT GAC AGT
AAG GAA T.2.5. Western blotting
Cellular proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and electrotransfered to a
nitrocellulose membrane (Bio-Rad, USA). Western blotting was
carried out by sequential incubation in 5% non-fat milk blocking
buffer at room temperature for 60 min, using the following anti-
bodies: LSD1 (Abcam, USA), 1:2000; H3K4me1 (Millipore, USA),
1:2000; H3K4me2 (Millipore, USA), 1:500; H3K9me1 (Millipore,
USA), 1:1000; H3K9me2 (Millipore, USA), 1:2000. Following over-
night incubation at 4 C, the secondary antibodies were added
and incubated for 60 min at 4 C. HRP-GAPDH (Kangchen, China)
was used as the loading control.
2.6. RNA isolation, reverse transcription and quantitative reverse
transcription (RT)-PCR
Total RNA from cell culture was extracted using the Trizol re-
agent, according to the manufacturer’s protocol (Takara, Japan).
The RNA samples were digested with DNase I (Takara, Japan), then
reverse-transcribed into cDNAs and sequence ampliﬁed by Quanti-
tative RT-PCR (Eco™ Real-Time PCR system, USA). According to the
manufacturer’s protocol, qRT-PCR was performed using the Fast-
Start Universal SYBR Green Master Mix kit (Roche, USA). Relative
mRNA levels of LSD1 were normalized to levels of the housekeep-
ing gene, GAPDH, and results were calculated using the 2DDCt
method. All samples were measured in triplicate. The following
primers were used: GAPDH, forward: 50-GAA GGT GAA GGT CGG
AGT CA-30; reverse 50-TTG AGG TCA ATG AAG GGG TC-30. LSD1, for-
ward: 50-TTC TGG AGG GTA TGG AGA CG-30; reverse: 50-CCT TCT
GGG TCT GTT GTG GT-30.
2.7. Cell migration and invasion assay
Using a scratch assay, the cultured cells were incubated for 24 h
in 6-well plates (Costar, USA) with RPMI 1640 plus 10% FCS until
90–100% conﬂuence. A 1 mm-wide linear scratch was applied
across the each well to evaluate cell migration. Subsequently,
2 ml of RPMI 1640 medium without FCS was introduced to repress
cell proliferation after washing. Tranylcypromine (Sigma–Aldrich,
USA) was added at a ﬁnal concentration of 0 lM, 50 lM and
250 lM in the treatment groups. 48 h after application of the
scratch, the width of the scratch was measured by CorelDRAW 9
(Corel Software Company, Canada).
Cell invasiveness was evaluated using a Transwell chamber as-
say (Costar, USA). Chamber membranes (8 lm, BD Falcon) were
pre-coated with 6 ll matrigel at 4 C overnight, and seeded with
1  105 cells. RPMI 1640 with 2% FCS supplement was added to
the upper chamber and 600 ll of RPMI 1640 (containing 20%
FCS) was added to the lower chamber. Cells were incubated for
48 h with or without treatment. The cells on the top of membranes
were removed, and the cells that penetrated the membrane were
ﬁxed in ethanol, followed by crystal violet staining. The number
of cells on the opposite side of the membrane was counted under
the microscope in four random ﬁelds of vision.
2.8. Statistical analysis
Quantitative data is expressed as mean ± SD in ﬁgures, and mul-
tiple comparisons between the groups was performed using SNK
method. Using SPSS 13.0 (SPSS Software Company, USA), one-
way ANOVA and student’s t-test were performed to determine
the signiﬁcance of the relationship between LSD1 expression and
the clinicopathological factors in patients with ESCC, including
sex, age, and pathological differentiation, inﬁltration, lymphatic
metastasis, and the overall survival. A Kaplan–Meier survival curve
Table 1
Correlation between LSD1 expression and clinical pathological data in the tissue
micro-array of 126 ESCC cases.
LSD1 P value
Low level High level
Sex
Male 57 41 0.44
Female 14 14
Age
660 35 34 0.16
>60 36 21
Pathological type
Medullary 5 7 0.19
Ulcerative 43 41
Cavity 5 2
Narrow 4 2
Fungating 13 3
Differentiation
Well 27 19 0.80
Moderately 33 32
Poorly 11 4
Inﬁltration
T1–2 37 29 0.94
T3–4 34 26
Lymphatic metastasis
Negative 52 30 0.03
Positive 19 25
Life-time
636 m 29 37 0.03
>36 m 42 18
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USA), and the signiﬁcance was calculated with the log-rank value.
The comparisons were considered statistically signiﬁcant when the
P value was less than 0.05.
3. Results
3.1. LSD1 expression was up-regulated in the ESCC tissues
To determine the association of LSD1 with the clinicopatholog-
ical characteristics of patients with ESCC, we examined and com-
pared expression levels of LSD1 in ESCC tissues, precancerous
lesions and paired normal tissues. The normal esophageal epithe-
lial cells demonstrated slight positive LSD1 expression, while pre-
cancerous lesions presented a higher LSD1 expression level. In the
normal and precancerous tissues, 51.7% and 73.9% of the cells were
LSD1-positive, respectively (Fig. 1A, P < 0.05). Nuclear LSD1 was
observed in 75.4% of LSD1-positive ESCC, of which, 43.7% of
LSD1-positive cells were associated with strengthened staining
(Fig. 1B), indicating that LSD1 was expressed at a relatively higher
level in ESCC relative to normal or precancerous tissues.
As shown in Table 1, LSD1 expression was not correlated with
any of the following clinicopathologic characteristics: sex, age,
inﬁltration, differentiation, and histological type (p > 0.05). How-
ever, we detected a signiﬁcant correlation between LSD1 expres-
sion and regional lymph node metastasis (LNM) in patients with
ESCC. ESCC patients with LNM expressed LSD1 (56.8%) at a higher
level than those without LNM (32.6%) (p < 0.05, Fig. 1C and D).
3.2. The over-expression of LSD1 predicts poor prognosis in patients
with ESCC
We evaluated the relationship between the LSD1 expression
and overall survival after surgery in patients with ESCC. The results
were similar in both cohorts between micro-assay results andFig. 1. LSD1 expression in normal esophageal epithelium, precancerous lesions and ESC
normal esophageal, precancerous, and cancerous tissues. (B) There were signiﬁcant dif
normal and precancerous tissues) (p < 0.05). (C) Representative IHC images showing the
without LNM. (D) The expression level of LSD1 was higher in the cases with LNM thantissue IHC staining (Fig. 2A and C). The ESCC patients with lower
LSD1 expression were associated with a survival beneﬁt, suggest-
ing LSD1 expression was signiﬁcantly associated with the progno-
sis of patients with ESCC. According to Kaplan–Meier curves, theC tissues. (A) LSD1 expression was investigated by immunohistochemistry (IHC) in
ferences of LSD1 expression between cancerous and non-cancer tissues (including
expression of LSD1 in the ESCC cases with lymph node metastasis (LNM), and those
those without LNM (p < 0.05).
Fig. 2. LSD1 expression was predictive of prognosis in patients with ESCC. (A) The discrepancy of LSD1 expression was detectable using ESCC micro-array. (B) Kaplan–Meier
curves showed the survival beneﬁt in ESCC patients with low LSD1 expression relative to that in ESCC patients with high LSD1 expression from the micro-array. (C) LSD1 was
expressed in ESCC tissue sections. (D) The survival curve derived from ESCC tissue slices was established similar to (B).
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of LSD1 were signiﬁcantly inferior to overall survival as compared
to ESCC patients with lower expression of LSD1 (p < 0.05, Fig. 2B
and D).3.3. Endogenous up-regulation of LSD1 promotes ESCC cell motility
and migration in vitro
We investigated LSD1 expression by RT-PCR and Western blot
in ESCC cell lines, including KYSE150, KYSE450 and EC109. We ob-
served a discrepancy in LSD1 expression between the three cells
lines (Fig. 3A and B). We explored the effects of endogenous
LSD1 on the migration and invasion of tumor cells. In the scratch
assay, KYSE450 cells migrated to the wounded area more efﬁ-
ciently than other two cell lines at 48 h (Fig. 3C). Similar results
were conﬁrmed in the transwell assay (Fig. 3D).
To further test whether LSD1 expression was required for ESCC
cell migration and invasion, ESCC cells were transfected with a len-
tivirus carrying shRNA speciﬁc for LSD1 (Fig. 3E and F). As shown in
Fig. 3G and H, knockdown of LSD1 signiﬁcantly inhibited migration
and invasion of LSD1-positive KYSE450 cells as compared with
cells transfected with control shRNA.3.4. LSD1 inhibitor, tranylcypromine, suppressed ESCC cells migration
and invasion via regulating demethylation level of H3K4me2/
H3K4me1
We discovered that the cells treated with tranylcypromine
(TCP), which acts as an inhibitor of LSD1, induced a similar effect
as knockdown of LSD1 in KYSE450 cells. With increasing concen-
trations of TCP, H3K4me1 expression decreased, while H3K4me2
expression increased. However, there was not a signiﬁcant change
in levels of H3K9me1 or H3K9me2 (Fig. 4A). Moreover, TCP sup-
pressed the migration and invasion of KYSE450 cells (Fig. 4B–E)
in a dose-dependent manner.4. Discussion
Recently, epigenetics has become a focus of cancer research.
The balance of methylation and demethylation in epigenetic mod-
iﬁcation affects gene expression and cellular activity. Previous
studies have demonstrated that aberrant histone lysine methyla-
tion in cancer is associated not only with the repression of chroma-
tin, but also with the repression of large chromosomal regions
[23,24]. Epigenetic modulation of LSD1 has been shown to play a
key role in carcinogenesis, in which LSD1 can prevent the accumu-
lation of the dimethyl groups of p53 from inducing apoptosis and
contributing to human carcinogenesis via a chromatin modiﬁca-
tion mechanism [25].
Previous reports have suggested that LSD1 could act as a bio-
marker for patients with aggressive phenotypes of breast cancer
[16], prostate cancer [18], and neuroblastoma [26], in which
LSD1 is frequently found at higher expression levels. However, only
few studies have implicated LSD1 with ESCC [9]. In the current
study, we found that LSD1 expression was relatively higher in ESCC
tissue compared with normal esophageal epithelial or atypical epi-
thelial hyperplastic tissues. Moreover, among the clinicopatholog-
ical parameters, LSD1 expression was signiﬁcantly correlated with
lymph node metastasis. This ﬁnding suggests that LSD1 may be
predictive of poorer prognosis in ESCC patients on the basis of
the observation that ESCC patients with up-regulated LSD1 expres-
sion were associated with lymph node metastasis and inferiority
for postoperative overall survival. Similarly, Lv and colleagues
found that the patients with a higher LSD1 expression had a poorer
prognosis in non-small cell lung cancer [20]. LSD1 has been shown
to function as an androgen receptor (AR)-dependent transcription
cofactors and promotes expression of androgen-dependent target
genes in prostate cancer cells [16,18]. Furthermore, high expres-
sion level of LSD1 is associated with a poorer survival and is predic-
tive of increased risk of postoperative local or metastatic
recurrence in prostate cancer [16]. Therefore, these results sug-
gested that aberrant overexpression of LSD1 may be predictive of
Fig. 3. LSD1 was associated with cell migration and invasion. (A and B) LSD1 was detected in KYSE150, KYSE450 and EC109 ESCC cell lines at both the RNA and protein level.
(C) The scratch within KYSE450 and KYSE150 monolayers healed more rapidly compared to EC109 monolayers. (D) A transwell assay was performed in the three cell lines,
and the histogram show that invaded EC109 cells were signiﬁcantly fewer compared to the other two cell lines. (E and F) The expression of LSD1 was knocked down in
KYSE450 cells by LSD1-shRNA1 and LSD1-shRNA2 on the basis of RT-PCR and Western blot. (G) The migration of the cells transfected with LSD1-shRNA1 and LSD1-shRNA2
compared to the control cell line. (H) According to a transwell assay, it was shown that the cells transfected with LSD1-shRNA1 and LSD1-shRNA2 featured signiﬁcantly
weakened invasion ability relative to control cells.
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including ESCC.
We investigated the relationship between LSD1 expression and
ESCC in vitro. In the wound and transwell assays, LSD1 knockdown
lead to a sharp decrease in the motility and invasion of KYSE450
compared to control shRNA treated cells. We detected methylation
of histone H3K4 in cells treated with the LSD1 inhibitor tranylcyp-
romine. Additionally, Western blot analysis uncovered an increase
in H3K4me2 and a decrease in H3K4me1methylation, reducing the
chance of transformation from H3K4me2 to H3K4me1 in a dose-
dependent manner. However, H3K9 methylation was dramatically
blocked in KYSE450 cells. These results implied that LSD1 may reg-
ulate downstream genes via demethylating H3K4me2. The inva-
sion of KYSE450 cells was signiﬁcantly attenuated with
increasing concentrations of tranylcypromine. This is consistent
with results previously observed in other tumors [20]. Therefore,
it is likely that the demethylation of LSD1 is important in promot-
ing tumor invasion, and tranylcypromine may be of therapeutic va-
lue for ESCC patients.
The aberrant over-expression of LSD1 in ESCC may be a good
candidate for a novel therapeutic molecular target [12].
First-generation drugs targeting the relatively promiscuous DNAmethylation and histone acetylation modiﬁers have had success
in the treatment of hematological tumors. If LSD1 inhibition leads
to signiﬁcant derepression of some genes, LSD1 may be an impor-
tant alternative target for therapy. In addition, development of his-
tone methyltransferase and demethylase inhibitors has recently
been reported [27]. In ESCC, over-expression of LSD1 should con-
tribute to gene repression that promotes cellular growth and
malignant progression. We plan to investigate this in future stud-
ies. Currently, there is vast knowledge concerning the roles of his-
tone demethylation in regulating biology of esophageal cancers.
Our study demonstrated that high LSD1 expression may modulate
expression of downstream genes through promoting demethyla-
tion of H3K4me2 in ESCC cells. This function of LSD1 may facilitate
metastasis, leading to poor prognosis of patients with ESCC. LSD1-
targeting shRNAs and the LSD1 inhibitors may reduce cell invasion.
However, the speciﬁc downstream target genes of LSD1 in esoph-
ageal cancer cells remain unclear.
A potential limitation of our study is that the sample size is rel-
atively small, which affects the ability of this study to represent a
wider population. However, this study suggests that LSD1 may
have predictive prognostic value in patients with ESCC. A random-
ized clinical trial (RCT) is necessary to detect the potential
Fig. 4. The effects of LSD1 inhibitor, tranylcypromine on the migration and invasiveness of ESCC cells. (A) After treating the cells with 50 lM and 250 lM tranylcypromine
(TCP) for 24 h we found H3K4me1 was decreased in parallel with the increasing TCP concentration, while H3K4me2 was increased. But there were no signiﬁcant difference in
H3K9me1 and H3K9me2 expression. (B and C) The scratch assay was performed in KYSE450 cells treated with vehicle control or with TCP (50 lM or 250 lM). The relative
width of the trace was measured at 48 h. (D and E) According to the transwell assay, the invasiveness of KYSE450 cells after 24 h was inhibited by TCP in a dose-dependent
manner.
Y. Yu et al. / Biochemical and Biophysical Research Communications 437 (2013) 192–198 197mechanism by which LSD1 induces tumorigenesis. Further studies
are designed to reveal the regulatory mechanisms of LSD1 in ESCC,
and to ﬁnd novel molecular targets that reduce postoperative
recurrence and metastasis in patients with ESCC.
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